- NCIt
- C7707
Loading cancer entity…
Loading cancer entity…
Clinical trials
76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | completed | Phase 2 | 30 | Wake Forest University Health SciencesOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00019968 | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 0 | Oct 31, 2023 | clinicaltrials |
| NCT03317457 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma(MEDISARC) | completed | Phase 2 | 103 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04138381 | Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)(SeliGIST) | unknown | Phase 1 / Phase 2 | 30 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT03590210 | Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas(NiTraSarc) | completed | Phase 2 | 92 | University Medicine GreifswaldOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01462630 | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02048722 | Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02050919 | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Yong ChenOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03121833 | Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma | completed | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT02849366 | Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01782313 | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | completed | Phase 2 | 58 | Northwestern UniversityOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | completed | Phase 2 | 69 | AGC Biologics S.p.A.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01169350 | 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | completed | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 4 | Aug 29, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT03121846 | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy | unknown | Phase 2 | 80 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT01222715 | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 4 | May 5, 2017 | clinicaltrials |
| NCT01719302 | Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 6 | University of VermontOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01623869 | Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01206140 | Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT01016015 | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | completed | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2015 | clinicaltrials |
| NCT00022542 | BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma | terminated | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00233948 | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma | terminated | Phase 1 / Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00331643 | Ixabepilone in Treating Young Patients With Refractory Solid Tumors | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2014 | clinicaltrials |
| NCT01281865 | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2014 | clinicaltrials |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | completed | Phase 2 | 147 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00937495 | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00330421 | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 27, 2013 | clinicaltrials |
| NCT00064324 | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087074 | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084630 | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2025source: clinicaltrials